Publish Date:
Friday, August 24, 2018 - 12:15
Applications open to present at Aus-Biotech Early State Investment Forum
Brisbane will be hosting Australia's major life sciences conference – the AusBiotech National Conference – at the Brisbane Convention Centre from 31 October to 2 November.
One of the key elements of this year’s conference is an Early State Investment Forum. The forum is designed to help research organisations and subject matter experts who are developing health-related technologies showing real promise to move to the next level of the commercialisation pipeline. This is a great opportunity for researchers in human therapeutics and enabling technologies to pitch to an expert investor panel of big pharma reps as well as corporate Venture Capitalists and early-stage investors.
Conditions and requirements:
• Successful applicants will be required to present on Thursday 1 November between 11.00am – 5.00pm at the AusBiotech 2018 conference in Brisbane. Each accepted presentation will be allocated 2 free BioIndustry exhibition hall access passes for the AusBiotech 2018 conference for use on the day (please note travel and accommodation is at the presenters own expense);
• Submissions are only open to investable projects from Australian research institutions or companies seeking seed or series A investment;
• Information included in the application process and presented on the day should be non-confidential;
• Applications from Institutions with Technology Transfer or Research Commercialisation Offices must have prior approval from the relevant technology transfer or commercialisation office, unless the entire IP rights to the project have been assigned to the individual submitting the proposal;
• Where relevant, applications are preferred from the associated technology transfer or commercialisation offices of the Institutions;
• Companies seeking seed or series A investment and Institutions without technology transfer or commercialisation offices should apply directly;
• Presenters will be allocated 7 minutes per presentation, with a further 5 minutes for Q&A from the investor panel;
• Upon acceptance, a template will be provided for the presentation, with a limit of 5 slides (not including the title slide) per presentation. Use of the template will be strictly enforced.
